nodes	percent_of_prediction	percent_of_DWPC	metapath
Captopril—MMP9—urinary bladder cancer	0.5	1	CbGaD
Captopril—ABCB1—Mitomycin—urinary bladder cancer	0.0494	0.318	CbGbCtD
Captopril—ALB—Fluorouracil—urinary bladder cancer	0.0233	0.15	CbGbCtD
Captopril—SLC22A6—Methotrexate—urinary bladder cancer	0.0151	0.0969	CbGbCtD
Captopril—ABCB1—Gemcitabine—urinary bladder cancer	0.0142	0.0915	CbGbCtD
Captopril—ALB—Methotrexate—urinary bladder cancer	0.0128	0.0825	CbGbCtD
Captopril—ABCB1—Cisplatin—urinary bladder cancer	0.0103	0.0665	CbGbCtD
Captopril—ABCB1—Etoposide—urinary bladder cancer	0.0102	0.0653	CbGbCtD
Captopril—REN—urine—urinary bladder cancer	0.00745	0.0847	CbGeAlD
Captopril—ABCB1—Doxorubicin—urinary bladder cancer	0.00693	0.0446	CbGbCtD
Captopril—ABCB1—Methotrexate—urinary bladder cancer	0.00671	0.0432	CbGbCtD
Captopril—CYP2D6—Doxorubicin—urinary bladder cancer	0.00653	0.042	CbGbCtD
Captopril—F2—urine—urinary bladder cancer	0.00519	0.0591	CbGeAlD
Captopril—ACE—umbilical vein—urinary bladder cancer	0.00393	0.0447	CbGeAlD
Captopril—LTA4H—prostate gland—urinary bladder cancer	0.00346	0.0394	CbGeAlD
Captopril—ACE—urine—urinary bladder cancer	0.00317	0.0361	CbGeAlD
Captopril—LTA4H—seminal vesicle—urinary bladder cancer	0.00293	0.0333	CbGeAlD
Captopril—MMP2—prostate gland—urinary bladder cancer	0.00246	0.0279	CbGeAlD
Captopril—LTA4H—smooth muscle tissue—urinary bladder cancer	0.00245	0.0279	CbGeAlD
Captopril—LTA4H—renal system—urinary bladder cancer	0.00236	0.0268	CbGeAlD
Captopril—LTA4H—urethra—urinary bladder cancer	0.00232	0.0264	CbGeAlD
Captopril—MMP9—prostate gland—urinary bladder cancer	0.00214	0.0243	CbGeAlD
Captopril—MMP2—seminal vesicle—urinary bladder cancer	0.00208	0.0236	CbGeAlD
Captopril—REN—epithelium—urinary bladder cancer	0.00196	0.0223	CbGeAlD
Captopril—REN—smooth muscle tissue—urinary bladder cancer	0.00189	0.0215	CbGeAlD
Captopril—LTA4H—female reproductive system—urinary bladder cancer	0.00189	0.0215	CbGeAlD
Captopril—F2—prostate gland—urinary bladder cancer	0.00186	0.0212	CbGeAlD
Captopril—REN—renal system—urinary bladder cancer	0.00182	0.0207	CbGeAlD
Captopril—MMP2—epithelium—urinary bladder cancer	0.00181	0.0205	CbGeAlD
Captopril—MMP2—smooth muscle tissue—urinary bladder cancer	0.00174	0.0198	CbGeAlD
Captopril—LTA4H—vagina—urinary bladder cancer	0.00171	0.0194	CbGeAlD
Captopril—MMP2—renal system—urinary bladder cancer	0.00167	0.019	CbGeAlD
Captopril—MMP2—urethra—urinary bladder cancer	0.00165	0.0187	CbGeAlD
Captopril—MMP9—epithelium—urinary bladder cancer	0.00157	0.0179	CbGeAlD
Captopril—CYP2D6—urine—urinary bladder cancer	0.00155	0.0177	CbGeAlD
Captopril—MMP9—smooth muscle tissue—urinary bladder cancer	0.00151	0.0172	CbGeAlD
Captopril—REN—female reproductive system—urinary bladder cancer	0.00146	0.0166	CbGeAlD
Captopril—MMP9—renal system—urinary bladder cancer	0.00146	0.0166	CbGeAlD
Captopril—F2—epithelium—urinary bladder cancer	0.00137	0.0156	CbGeAlD
Captopril—MMP2—female reproductive system—urinary bladder cancer	0.00134	0.0153	CbGeAlD
Captopril—F2—renal system—urinary bladder cancer	0.00127	0.0144	CbGeAlD
Captopril—MMP2—vagina—urinary bladder cancer	0.00121	0.0138	CbGeAlD
Captopril—SLC15A1—epithelium—urinary bladder cancer	0.00117	0.0133	CbGeAlD
Captopril—MMP9—female reproductive system—urinary bladder cancer	0.00117	0.0133	CbGeAlD
Captopril—ACE—prostate gland—urinary bladder cancer	0.00114	0.013	CbGeAlD
Captopril—LTA4H—lymph node—urinary bladder cancer	0.00111	0.0126	CbGeAlD
Captopril—SLC15A1—renal system—urinary bladder cancer	0.00108	0.0123	CbGeAlD
Captopril—F2—female reproductive system—urinary bladder cancer	0.00102	0.0116	CbGeAlD
Captopril—ACE—seminal vesicle—urinary bladder cancer	0.000963	0.011	CbGeAlD
Captopril—ACE—epithelium—urinary bladder cancer	0.000837	0.00952	CbGeAlD
Captopril—ACE—smooth muscle tissue—urinary bladder cancer	0.000806	0.00917	CbGeAlD
Captopril—MMP2—lymph node—urinary bladder cancer	0.000785	0.00892	CbGeAlD
Captopril—SLC15A1—vagina—urinary bladder cancer	0.000784	0.00892	CbGeAlD
Captopril—ACE—renal system—urinary bladder cancer	0.000776	0.00883	CbGeAlD
Captopril—ACE—urethra—urinary bladder cancer	0.000763	0.00867	CbGeAlD
Captopril—MMP9—lymph node—urinary bladder cancer	0.000682	0.00776	CbGeAlD
Captopril—ACE—female reproductive system—urinary bladder cancer	0.000622	0.00707	CbGeAlD
Captopril—ABCB1—prostate gland—urinary bladder cancer	0.000401	0.00456	CbGeAlD
Captopril—ALB—lymph node—urinary bladder cancer	0.00038	0.00432	CbGeAlD
Captopril—CYP2D6—renal system—urinary bladder cancer	0.00038	0.00432	CbGeAlD
Captopril—ACE—lymph node—urinary bladder cancer	0.000364	0.00414	CbGeAlD
Captopril—ABCB1—seminal vesicle—urinary bladder cancer	0.000339	0.00386	CbGeAlD
Captopril—CYP2D6—female reproductive system—urinary bladder cancer	0.000304	0.00346	CbGeAlD
Captopril—ABCB1—epithelium—urinary bladder cancer	0.000295	0.00335	CbGeAlD
Captopril—ABCB1—renal system—urinary bladder cancer	0.000273	0.00311	CbGeAlD
Captopril—ABCB1—urethra—urinary bladder cancer	0.000268	0.00305	CbGeAlD
Captopril—ABCB1—female reproductive system—urinary bladder cancer	0.000219	0.00249	CbGeAlD
Captopril—ABCB1—vagina—urinary bladder cancer	0.000198	0.00225	CbGeAlD
Captopril—Fatigue—Gemcitabine—urinary bladder cancer	0.000133	0.000955	CcSEcCtD
Captopril—Confusional state—Etoposide—urinary bladder cancer	0.000132	0.000953	CcSEcCtD
Captopril—Muscular weakness—Epirubicin—urinary bladder cancer	0.000132	0.000951	CcSEcCtD
Captopril—Cardiac arrest—Doxorubicin—urinary bladder cancer	0.000132	0.000949	CcSEcCtD
Captopril—Constipation—Gemcitabine—urinary bladder cancer	0.000131	0.000947	CcSEcCtD
Captopril—Decreased appetite—Fluorouracil—urinary bladder cancer	0.000131	0.000946	CcSEcCtD
Captopril—Pancytopenia—Methotrexate—urinary bladder cancer	0.000131	0.000946	CcSEcCtD
Captopril—Anaphylactic shock—Etoposide—urinary bladder cancer	0.000131	0.000945	CcSEcCtD
Captopril—Asthenia—Thiotepa—urinary bladder cancer	0.000131	0.000944	CcSEcCtD
Captopril—Musculoskeletal discomfort—Cisplatin—urinary bladder cancer	0.000131	0.00094	CcSEcCtD
Captopril—Ataxia—Doxorubicin—urinary bladder cancer	0.00013	0.000938	CcSEcCtD
Captopril—Neutropenia—Methotrexate—urinary bladder cancer	0.000129	0.000931	CcSEcCtD
Captopril—Pruritus—Thiotepa—urinary bladder cancer	0.000129	0.000931	CcSEcCtD
Captopril—Paraesthesia—Cisplatin—urinary bladder cancer	0.000129	0.000927	CcSEcCtD
Captopril—Thrombocytopenia—Etoposide—urinary bladder cancer	0.000129	0.000926	CcSEcCtD
Captopril—Tachycardia—Etoposide—urinary bladder cancer	0.000128	0.000923	CcSEcCtD
Captopril—Eosinophilia—Epirubicin—urinary bladder cancer	0.000128	0.000923	CcSEcCtD
Captopril—ABCB1—lymph node—urinary bladder cancer	0.000128	0.00146	CbGeAlD
Captopril—Dyspnoea—Cisplatin—urinary bladder cancer	0.000128	0.00092	CcSEcCtD
Captopril—Erectile dysfunction—Methotrexate—urinary bladder cancer	0.000127	0.000917	CcSEcCtD
Captopril—Pancreatitis—Epirubicin—urinary bladder cancer	0.000127	0.000914	CcSEcCtD
Captopril—Feeling abnormal—Gemcitabine—urinary bladder cancer	0.000127	0.000912	CcSEcCtD
Captopril—Orthostatic hypotension—Doxorubicin—urinary bladder cancer	0.000127	0.000911	CcSEcCtD
Captopril—Photosensitivity reaction—Methotrexate—urinary bladder cancer	0.000126	0.000909	CcSEcCtD
Captopril—Angina pectoris—Epirubicin—urinary bladder cancer	0.000126	0.000908	CcSEcCtD
Captopril—Anorexia—Etoposide—urinary bladder cancer	0.000125	0.000901	CcSEcCtD
Captopril—Diarrhoea—Thiotepa—urinary bladder cancer	0.000125	0.000901	CcSEcCtD
Captopril—Decreased appetite—Cisplatin—urinary bladder cancer	0.000125	0.000897	CcSEcCtD
Captopril—Feeling abnormal—Fluorouracil—urinary bladder cancer	0.000125	0.000897	CcSEcCtD
Captopril—Pancytopenia—Epirubicin—urinary bladder cancer	0.000123	0.000885	CcSEcCtD
Captopril—Hypotension—Etoposide—urinary bladder cancer	0.000123	0.000883	CcSEcCtD
Captopril—Stevens-Johnson syndrome—Methotrexate—urinary bladder cancer	0.000122	0.00088	CcSEcCtD
Captopril—Muscular weakness—Doxorubicin—urinary bladder cancer	0.000122	0.00088	CcSEcCtD
Captopril—Body temperature increased—Gemcitabine—urinary bladder cancer	0.000122	0.000875	CcSEcCtD
Captopril—Renal failure—Methotrexate—urinary bladder cancer	0.000121	0.000873	CcSEcCtD
Captopril—Neutropenia—Epirubicin—urinary bladder cancer	0.000121	0.000871	CcSEcCtD
Captopril—Dizziness—Thiotepa—urinary bladder cancer	0.000121	0.00087	CcSEcCtD
Captopril—Stomatitis—Methotrexate—urinary bladder cancer	0.00012	0.000866	CcSEcCtD
Captopril—Pollakiuria—Epirubicin—urinary bladder cancer	0.00012	0.000861	CcSEcCtD
Captopril—Body temperature increased—Fluorouracil—urinary bladder cancer	0.000119	0.000861	CcSEcCtD
Captopril—Eosinophilia—Doxorubicin—urinary bladder cancer	0.000119	0.000854	CcSEcCtD
Captopril—Photosensitivity reaction—Epirubicin—urinary bladder cancer	0.000118	0.000851	CcSEcCtD
Captopril—Feeling abnormal—Cisplatin—urinary bladder cancer	0.000118	0.00085	CcSEcCtD
Captopril—Paraesthesia—Etoposide—urinary bladder cancer	0.000118	0.000849	CcSEcCtD
Captopril—Pancreatitis—Doxorubicin—urinary bladder cancer	0.000117	0.000845	CcSEcCtD
Captopril—Weight decreased—Epirubicin—urinary bladder cancer	0.000117	0.000843	CcSEcCtD
Captopril—Dyspnoea—Etoposide—urinary bladder cancer	0.000117	0.000843	CcSEcCtD
Captopril—Somnolence—Etoposide—urinary bladder cancer	0.000117	0.000841	CcSEcCtD
Captopril—Angina pectoris—Doxorubicin—urinary bladder cancer	0.000117	0.00084	CcSEcCtD
Captopril—Vomiting—Thiotepa—urinary bladder cancer	0.000116	0.000837	CcSEcCtD
Captopril—Rash—Thiotepa—urinary bladder cancer	0.000115	0.00083	CcSEcCtD
Captopril—Dermatitis—Thiotepa—urinary bladder cancer	0.000115	0.000829	CcSEcCtD
Captopril—Agranulocytosis—Methotrexate—urinary bladder cancer	0.000115	0.000829	CcSEcCtD
Captopril—Headache—Thiotepa—urinary bladder cancer	0.000114	0.000825	CcSEcCtD
Captopril—Stevens-Johnson syndrome—Epirubicin—urinary bladder cancer	0.000114	0.000824	CcSEcCtD
Captopril—Decreased appetite—Etoposide—urinary bladder cancer	0.000114	0.000822	CcSEcCtD
Captopril—Pancytopenia—Doxorubicin—urinary bladder cancer	0.000114	0.000819	CcSEcCtD
Captopril—Renal failure—Epirubicin—urinary bladder cancer	0.000113	0.000817	CcSEcCtD
Captopril—Body temperature increased—Cisplatin—urinary bladder cancer	0.000113	0.000816	CcSEcCtD
Captopril—Fatigue—Etoposide—urinary bladder cancer	0.000113	0.000815	CcSEcCtD
Captopril—Stomatitis—Epirubicin—urinary bladder cancer	0.000112	0.00081	CcSEcCtD
Captopril—Jaundice—Epirubicin—urinary bladder cancer	0.000112	0.00081	CcSEcCtD
Captopril—Constipation—Etoposide—urinary bladder cancer	0.000112	0.000809	CcSEcCtD
Captopril—Neutropenia—Doxorubicin—urinary bladder cancer	0.000112	0.000806	CcSEcCtD
Captopril—Hepatitis—Methotrexate—urinary bladder cancer	0.000111	0.000797	CcSEcCtD
Captopril—Pollakiuria—Doxorubicin—urinary bladder cancer	0.000111	0.000797	CcSEcCtD
Captopril—Asthenia—Gemcitabine—urinary bladder cancer	0.00011	0.000794	CcSEcCtD
Captopril—Pharyngitis—Methotrexate—urinary bladder cancer	0.00011	0.000791	CcSEcCtD
Captopril—Photosensitivity reaction—Doxorubicin—urinary bladder cancer	0.000109	0.000787	CcSEcCtD
Captopril—Pruritus—Gemcitabine—urinary bladder cancer	0.000109	0.000783	CcSEcCtD
Captopril—Nausea—Thiotepa—urinary bladder cancer	0.000109	0.000782	CcSEcCtD
Captopril—Weight decreased—Doxorubicin—urinary bladder cancer	0.000108	0.00078	CcSEcCtD
Captopril—Feeling abnormal—Etoposide—urinary bladder cancer	0.000108	0.000779	CcSEcCtD
Captopril—Agranulocytosis—Epirubicin—urinary bladder cancer	0.000108	0.000775	CcSEcCtD
Captopril—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000107	0.000773	CcSEcCtD
Captopril—Pruritus—Fluorouracil—urinary bladder cancer	0.000107	0.00077	CcSEcCtD
Captopril—Stevens-Johnson syndrome—Doxorubicin—urinary bladder cancer	0.000106	0.000762	CcSEcCtD
Captopril—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000105	0.000758	CcSEcCtD
Captopril—Renal failure—Doxorubicin—urinary bladder cancer	0.000105	0.000756	CcSEcCtD
Captopril—Erythema multiforme—Methotrexate—urinary bladder cancer	0.000105	0.000754	CcSEcCtD
Captopril—Jaundice—Doxorubicin—urinary bladder cancer	0.000104	0.000749	CcSEcCtD
Captopril—Stomatitis—Doxorubicin—urinary bladder cancer	0.000104	0.000749	CcSEcCtD
Captopril—Rhinitis—Epirubicin—urinary bladder cancer	0.000104	0.000748	CcSEcCtD
Captopril—Body temperature increased—Etoposide—urinary bladder cancer	0.000104	0.000747	CcSEcCtD
Captopril—Abdominal pain—Etoposide—urinary bladder cancer	0.000104	0.000747	CcSEcCtD
Captopril—Hepatitis—Epirubicin—urinary bladder cancer	0.000104	0.000746	CcSEcCtD
Captopril—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000103	0.000745	CcSEcCtD
Captopril—Asthenia—Cisplatin—urinary bladder cancer	0.000103	0.00074	CcSEcCtD
Captopril—Pharyngitis—Epirubicin—urinary bladder cancer	0.000103	0.00074	CcSEcCtD
Captopril—Dizziness—Fluorouracil—urinary bladder cancer	9.99e-05	0.00072	CcSEcCtD
Captopril—Agranulocytosis—Doxorubicin—urinary bladder cancer	9.96e-05	0.000718	CcSEcCtD
Captopril—Diarrhoea—Cisplatin—urinary bladder cancer	9.8e-05	0.000706	CcSEcCtD
Captopril—Erythema multiforme—Epirubicin—urinary bladder cancer	9.79e-05	0.000705	CcSEcCtD
Captopril—Alopecia—Methotrexate—urinary bladder cancer	9.78e-05	0.000704	CcSEcCtD
Captopril—Vomiting—Gemcitabine—urinary bladder cancer	9.77e-05	0.000704	CcSEcCtD
Captopril—Rash—Gemcitabine—urinary bladder cancer	9.69e-05	0.000698	CcSEcCtD
Captopril—Dermatitis—Gemcitabine—urinary bladder cancer	9.68e-05	0.000697	CcSEcCtD
Captopril—Headache—Gemcitabine—urinary bladder cancer	9.63e-05	0.000694	CcSEcCtD
Captopril—Flushing—Epirubicin—urinary bladder cancer	9.61e-05	0.000692	CcSEcCtD
Captopril—Vomiting—Fluorouracil—urinary bladder cancer	9.61e-05	0.000692	CcSEcCtD
Captopril—Rhinitis—Doxorubicin—urinary bladder cancer	9.61e-05	0.000692	CcSEcCtD
Captopril—Hepatitis—Doxorubicin—urinary bladder cancer	9.58e-05	0.00069	CcSEcCtD
Captopril—Rash—Fluorouracil—urinary bladder cancer	9.53e-05	0.000686	CcSEcCtD
Captopril—Dermatitis—Fluorouracil—urinary bladder cancer	9.52e-05	0.000686	CcSEcCtD
Captopril—Pharyngitis—Doxorubicin—urinary bladder cancer	9.51e-05	0.000685	CcSEcCtD
Captopril—Headache—Fluorouracil—urinary bladder cancer	9.47e-05	0.000682	CcSEcCtD
Captopril—Dysgeusia—Methotrexate—urinary bladder cancer	9.43e-05	0.00068	CcSEcCtD
Captopril—Asthenia—Etoposide—urinary bladder cancer	9.42e-05	0.000678	CcSEcCtD
Captopril—Pruritus—Etoposide—urinary bladder cancer	9.29e-05	0.000669	CcSEcCtD
Captopril—Alopecia—Epirubicin—urinary bladder cancer	9.15e-05	0.000659	CcSEcCtD
Captopril—Nausea—Gemcitabine—urinary bladder cancer	9.13e-05	0.000658	CcSEcCtD
Captopril—Vomiting—Cisplatin—urinary bladder cancer	9.11e-05	0.000656	CcSEcCtD
Captopril—Vision blurred—Methotrexate—urinary bladder cancer	9.08e-05	0.000654	CcSEcCtD
Captopril—Erythema multiforme—Doxorubicin—urinary bladder cancer	9.06e-05	0.000653	CcSEcCtD
Captopril—Rash—Cisplatin—urinary bladder cancer	9.03e-05	0.000651	CcSEcCtD
Captopril—Dermatitis—Cisplatin—urinary bladder cancer	9.02e-05	0.00065	CcSEcCtD
Captopril—Diarrhoea—Etoposide—urinary bladder cancer	8.98e-05	0.000647	CcSEcCtD
Captopril—Nausea—Fluorouracil—urinary bladder cancer	8.98e-05	0.000647	CcSEcCtD
Captopril—Ill-defined disorder—Methotrexate—urinary bladder cancer	8.94e-05	0.000644	CcSEcCtD
Captopril—Anaemia—Methotrexate—urinary bladder cancer	8.9e-05	0.000641	CcSEcCtD
Captopril—Flushing—Doxorubicin—urinary bladder cancer	8.89e-05	0.000641	CcSEcCtD
Captopril—Tension—Epirubicin—urinary bladder cancer	8.85e-05	0.000637	CcSEcCtD
Captopril—Dysgeusia—Epirubicin—urinary bladder cancer	8.83e-05	0.000636	CcSEcCtD
Captopril—Nervousness—Epirubicin—urinary bladder cancer	8.76e-05	0.000631	CcSEcCtD
Captopril—Malaise—Methotrexate—urinary bladder cancer	8.69e-05	0.000626	CcSEcCtD
Captopril—Dizziness—Etoposide—urinary bladder cancer	8.68e-05	0.000625	CcSEcCtD
Captopril—Nausea—Cisplatin—urinary bladder cancer	8.51e-05	0.000613	CcSEcCtD
Captopril—Vision blurred—Epirubicin—urinary bladder cancer	8.5e-05	0.000612	CcSEcCtD
Captopril—Alopecia—Doxorubicin—urinary bladder cancer	8.47e-05	0.00061	CcSEcCtD
Captopril—Cough—Methotrexate—urinary bladder cancer	8.41e-05	0.000606	CcSEcCtD
Captopril—Ill-defined disorder—Epirubicin—urinary bladder cancer	8.36e-05	0.000603	CcSEcCtD
Captopril—Vomiting—Etoposide—urinary bladder cancer	8.35e-05	0.000601	CcSEcCtD
Captopril—Anaemia—Epirubicin—urinary bladder cancer	8.33e-05	0.0006	CcSEcCtD
Captopril—Rash—Etoposide—urinary bladder cancer	8.28e-05	0.000596	CcSEcCtD
Captopril—Dermatitis—Etoposide—urinary bladder cancer	8.27e-05	0.000596	CcSEcCtD
Captopril—Headache—Etoposide—urinary bladder cancer	8.22e-05	0.000592	CcSEcCtD
Captopril—Chest pain—Methotrexate—urinary bladder cancer	8.2e-05	0.000591	CcSEcCtD
Captopril—Arthralgia—Methotrexate—urinary bladder cancer	8.2e-05	0.000591	CcSEcCtD
Captopril—Myalgia—Methotrexate—urinary bladder cancer	8.2e-05	0.000591	CcSEcCtD
Captopril—Tension—Doxorubicin—urinary bladder cancer	8.19e-05	0.00059	CcSEcCtD
Captopril—Dysgeusia—Doxorubicin—urinary bladder cancer	8.17e-05	0.000588	CcSEcCtD
Captopril—Malaise—Epirubicin—urinary bladder cancer	8.13e-05	0.000586	CcSEcCtD
Captopril—Discomfort—Methotrexate—urinary bladder cancer	8.1e-05	0.000584	CcSEcCtD
Captopril—Nervousness—Doxorubicin—urinary bladder cancer	8.1e-05	0.000584	CcSEcCtD
Captopril—Syncope—Epirubicin—urinary bladder cancer	8.08e-05	0.000582	CcSEcCtD
Captopril—Palpitations—Epirubicin—urinary bladder cancer	7.97e-05	0.000574	CcSEcCtD
Captopril—Confusional state—Methotrexate—urinary bladder cancer	7.93e-05	0.000571	CcSEcCtD
Captopril—Loss of consciousness—Epirubicin—urinary bladder cancer	7.92e-05	0.000571	CcSEcCtD
Captopril—Cough—Epirubicin—urinary bladder cancer	7.87e-05	0.000567	CcSEcCtD
Captopril—Anaphylactic shock—Methotrexate—urinary bladder cancer	7.86e-05	0.000566	CcSEcCtD
Captopril—Vision blurred—Doxorubicin—urinary bladder cancer	7.86e-05	0.000566	CcSEcCtD
Captopril—Nausea—Etoposide—urinary bladder cancer	7.8e-05	0.000562	CcSEcCtD
Captopril—Ill-defined disorder—Doxorubicin—urinary bladder cancer	7.74e-05	0.000558	CcSEcCtD
Captopril—Anaemia—Doxorubicin—urinary bladder cancer	7.71e-05	0.000555	CcSEcCtD
Captopril—Thrombocytopenia—Methotrexate—urinary bladder cancer	7.7e-05	0.000554	CcSEcCtD
Captopril—Chest pain—Epirubicin—urinary bladder cancer	7.67e-05	0.000553	CcSEcCtD
Captopril—Arthralgia—Epirubicin—urinary bladder cancer	7.67e-05	0.000553	CcSEcCtD
Captopril—Myalgia—Epirubicin—urinary bladder cancer	7.67e-05	0.000553	CcSEcCtD
Captopril—Discomfort—Epirubicin—urinary bladder cancer	7.58e-05	0.000546	CcSEcCtD
Captopril—Malaise—Doxorubicin—urinary bladder cancer	7.52e-05	0.000542	CcSEcCtD
Captopril—Dry mouth—Epirubicin—urinary bladder cancer	7.51e-05	0.000541	CcSEcCtD
Captopril—Anorexia—Methotrexate—urinary bladder cancer	7.49e-05	0.00054	CcSEcCtD
Captopril—Syncope—Doxorubicin—urinary bladder cancer	7.48e-05	0.000539	CcSEcCtD
Captopril—Confusional state—Epirubicin—urinary bladder cancer	7.42e-05	0.000534	CcSEcCtD
Captopril—Palpitations—Doxorubicin—urinary bladder cancer	7.37e-05	0.000531	CcSEcCtD
Captopril—Anaphylactic shock—Epirubicin—urinary bladder cancer	7.36e-05	0.00053	CcSEcCtD
Captopril—Hypotension—Methotrexate—urinary bladder cancer	7.35e-05	0.000529	CcSEcCtD
Captopril—Loss of consciousness—Doxorubicin—urinary bladder cancer	7.33e-05	0.000528	CcSEcCtD
Captopril—Cough—Doxorubicin—urinary bladder cancer	7.28e-05	0.000524	CcSEcCtD
Captopril—Shock—Epirubicin—urinary bladder cancer	7.24e-05	0.000521	CcSEcCtD
Captopril—Thrombocytopenia—Epirubicin—urinary bladder cancer	7.2e-05	0.000519	CcSEcCtD
Captopril—Tachycardia—Epirubicin—urinary bladder cancer	7.18e-05	0.000517	CcSEcCtD
Captopril—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	7.16e-05	0.000516	CcSEcCtD
Captopril—Insomnia—Methotrexate—urinary bladder cancer	7.11e-05	0.000512	CcSEcCtD
Captopril—Chest pain—Doxorubicin—urinary bladder cancer	7.1e-05	0.000512	CcSEcCtD
Captopril—Myalgia—Doxorubicin—urinary bladder cancer	7.1e-05	0.000512	CcSEcCtD
Captopril—Arthralgia—Doxorubicin—urinary bladder cancer	7.1e-05	0.000512	CcSEcCtD
Captopril—Paraesthesia—Methotrexate—urinary bladder cancer	7.06e-05	0.000509	CcSEcCtD
Captopril—Discomfort—Doxorubicin—urinary bladder cancer	7.02e-05	0.000505	CcSEcCtD
Captopril—Anorexia—Epirubicin—urinary bladder cancer	7.01e-05	0.000505	CcSEcCtD
Captopril—Dyspnoea—Methotrexate—urinary bladder cancer	7.01e-05	0.000505	CcSEcCtD
Captopril—Somnolence—Methotrexate—urinary bladder cancer	6.99e-05	0.000503	CcSEcCtD
Captopril—Dry mouth—Doxorubicin—urinary bladder cancer	6.95e-05	0.0005	CcSEcCtD
Captopril—Dyspepsia—Methotrexate—urinary bladder cancer	6.92e-05	0.000499	CcSEcCtD
Captopril—Hypotension—Epirubicin—urinary bladder cancer	6.87e-05	0.000495	CcSEcCtD
Captopril—Confusional state—Doxorubicin—urinary bladder cancer	6.86e-05	0.000494	CcSEcCtD
Captopril—Decreased appetite—Methotrexate—urinary bladder cancer	6.83e-05	0.000492	CcSEcCtD
Captopril—Anaphylactic shock—Doxorubicin—urinary bladder cancer	6.81e-05	0.00049	CcSEcCtD
Captopril—Fatigue—Methotrexate—urinary bladder cancer	6.78e-05	0.000488	CcSEcCtD
Captopril—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	6.7e-05	0.000483	CcSEcCtD
Captopril—Shock—Doxorubicin—urinary bladder cancer	6.7e-05	0.000482	CcSEcCtD
Captopril—Thrombocytopenia—Doxorubicin—urinary bladder cancer	6.67e-05	0.00048	CcSEcCtD
Captopril—Insomnia—Epirubicin—urinary bladder cancer	6.65e-05	0.000479	CcSEcCtD
Captopril—Tachycardia—Doxorubicin—urinary bladder cancer	6.64e-05	0.000479	CcSEcCtD
Captopril—Paraesthesia—Epirubicin—urinary bladder cancer	6.61e-05	0.000476	CcSEcCtD
Captopril—Dyspnoea—Epirubicin—urinary bladder cancer	6.56e-05	0.000473	CcSEcCtD
Captopril—Somnolence—Epirubicin—urinary bladder cancer	6.54e-05	0.000471	CcSEcCtD
Captopril—Anorexia—Doxorubicin—urinary bladder cancer	6.49e-05	0.000467	CcSEcCtD
Captopril—Feeling abnormal—Methotrexate—urinary bladder cancer	6.48e-05	0.000467	CcSEcCtD
Captopril—Dyspepsia—Epirubicin—urinary bladder cancer	6.48e-05	0.000467	CcSEcCtD
Captopril—Gastrointestinal pain—Methotrexate—urinary bladder cancer	6.43e-05	0.000463	CcSEcCtD
Captopril—Decreased appetite—Epirubicin—urinary bladder cancer	6.4e-05	0.000461	CcSEcCtD
Captopril—Hypotension—Doxorubicin—urinary bladder cancer	6.36e-05	0.000458	CcSEcCtD
Captopril—Fatigue—Epirubicin—urinary bladder cancer	6.34e-05	0.000457	CcSEcCtD
Captopril—Constipation—Epirubicin—urinary bladder cancer	6.29e-05	0.000453	CcSEcCtD
Captopril—Body temperature increased—Methotrexate—urinary bladder cancer	6.21e-05	0.000448	CcSEcCtD
Captopril—Abdominal pain—Methotrexate—urinary bladder cancer	6.21e-05	0.000448	CcSEcCtD
Captopril—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	6.2e-05	0.000447	CcSEcCtD
Captopril—Insomnia—Doxorubicin—urinary bladder cancer	6.16e-05	0.000444	CcSEcCtD
Captopril—Paraesthesia—Doxorubicin—urinary bladder cancer	6.11e-05	0.00044	CcSEcCtD
Captopril—Dyspnoea—Doxorubicin—urinary bladder cancer	6.07e-05	0.000437	CcSEcCtD
Captopril—Feeling abnormal—Epirubicin—urinary bladder cancer	6.06e-05	0.000437	CcSEcCtD
Captopril—Somnolence—Doxorubicin—urinary bladder cancer	6.05e-05	0.000436	CcSEcCtD
Captopril—Gastrointestinal pain—Epirubicin—urinary bladder cancer	6.02e-05	0.000433	CcSEcCtD
Captopril—Dyspepsia—Doxorubicin—urinary bladder cancer	5.99e-05	0.000432	CcSEcCtD
Captopril—Decreased appetite—Doxorubicin—urinary bladder cancer	5.92e-05	0.000426	CcSEcCtD
Captopril—Fatigue—Doxorubicin—urinary bladder cancer	5.87e-05	0.000423	CcSEcCtD
Captopril—Constipation—Doxorubicin—urinary bladder cancer	5.82e-05	0.000419	CcSEcCtD
Captopril—Abdominal pain—Epirubicin—urinary bladder cancer	5.82e-05	0.000419	CcSEcCtD
Captopril—Body temperature increased—Epirubicin—urinary bladder cancer	5.82e-05	0.000419	CcSEcCtD
Captopril—Asthenia—Methotrexate—urinary bladder cancer	5.64e-05	0.000406	CcSEcCtD
Captopril—Feeling abnormal—Doxorubicin—urinary bladder cancer	5.61e-05	0.000404	CcSEcCtD
Captopril—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	5.57e-05	0.000401	CcSEcCtD
Captopril—Pruritus—Methotrexate—urinary bladder cancer	5.56e-05	0.000401	CcSEcCtD
Captopril—Abdominal pain—Doxorubicin—urinary bladder cancer	5.38e-05	0.000388	CcSEcCtD
Captopril—Body temperature increased—Doxorubicin—urinary bladder cancer	5.38e-05	0.000388	CcSEcCtD
Captopril—Diarrhoea—Methotrexate—urinary bladder cancer	5.38e-05	0.000387	CcSEcCtD
Captopril—Asthenia—Epirubicin—urinary bladder cancer	5.28e-05	0.00038	CcSEcCtD
Captopril—Pruritus—Epirubicin—urinary bladder cancer	5.21e-05	0.000375	CcSEcCtD
Captopril—Dizziness—Methotrexate—urinary bladder cancer	5.2e-05	0.000374	CcSEcCtD
Captopril—Diarrhoea—Epirubicin—urinary bladder cancer	5.03e-05	0.000363	CcSEcCtD
Captopril—Vomiting—Methotrexate—urinary bladder cancer	5e-05	0.00036	CcSEcCtD
Captopril—Rash—Methotrexate—urinary bladder cancer	4.96e-05	0.000357	CcSEcCtD
Captopril—Dermatitis—Methotrexate—urinary bladder cancer	4.95e-05	0.000357	CcSEcCtD
Captopril—Headache—Methotrexate—urinary bladder cancer	4.93e-05	0.000355	CcSEcCtD
Captopril—Asthenia—Doxorubicin—urinary bladder cancer	4.88e-05	0.000352	CcSEcCtD
Captopril—Dizziness—Epirubicin—urinary bladder cancer	4.87e-05	0.00035	CcSEcCtD
Captopril—Pruritus—Doxorubicin—urinary bladder cancer	4.82e-05	0.000347	CcSEcCtD
Captopril—Vomiting—Epirubicin—urinary bladder cancer	4.68e-05	0.000337	CcSEcCtD
Captopril—Nausea—Methotrexate—urinary bladder cancer	4.67e-05	0.000336	CcSEcCtD
Captopril—Diarrhoea—Doxorubicin—urinary bladder cancer	4.66e-05	0.000336	CcSEcCtD
Captopril—Rash—Epirubicin—urinary bladder cancer	4.64e-05	0.000334	CcSEcCtD
Captopril—Dermatitis—Epirubicin—urinary bladder cancer	4.63e-05	0.000334	CcSEcCtD
Captopril—Headache—Epirubicin—urinary bladder cancer	4.61e-05	0.000332	CcSEcCtD
Captopril—Dizziness—Doxorubicin—urinary bladder cancer	4.5e-05	0.000324	CcSEcCtD
Captopril—Nausea—Epirubicin—urinary bladder cancer	4.37e-05	0.000315	CcSEcCtD
Captopril—Vomiting—Doxorubicin—urinary bladder cancer	4.33e-05	0.000312	CcSEcCtD
Captopril—Rash—Doxorubicin—urinary bladder cancer	4.29e-05	0.000309	CcSEcCtD
Captopril—Dermatitis—Doxorubicin—urinary bladder cancer	4.29e-05	0.000309	CcSEcCtD
Captopril—Headache—Doxorubicin—urinary bladder cancer	4.26e-05	0.000307	CcSEcCtD
Captopril—SLC22A6—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	4.05e-05	0.000344	CbGpPWpGaD
Captopril—Nausea—Doxorubicin—urinary bladder cancer	4.04e-05	0.000291	CcSEcCtD
Captopril—LTA4H—Metabolism—PTEN—urinary bladder cancer	3.98e-05	0.000339	CbGpPWpGaD
Captopril—ACE—Metabolism of proteins—IGF1—urinary bladder cancer	3.95e-05	0.000336	CbGpPWpGaD
Captopril—ALB—Vitamin B12 Metabolism—TNF—urinary bladder cancer	3.94e-05	0.000335	CbGpPWpGaD
Captopril—MMP9—Developmental Biology—PPARG—urinary bladder cancer	3.94e-05	0.000335	CbGpPWpGaD
Captopril—MMP2—Developmental Biology—EP300—urinary bladder cancer	3.93e-05	0.000334	CbGpPWpGaD
Captopril—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—urinary bladder cancer	3.83e-05	0.000326	CbGpPWpGaD
Captopril—MMP2—Developmental Biology—SRC—urinary bladder cancer	3.82e-05	0.000325	CbGpPWpGaD
Captopril—ALB—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	3.82e-05	0.000325	CbGpPWpGaD
Captopril—LTA4H—Metabolism—EP300—urinary bladder cancer	3.8e-05	0.000323	CbGpPWpGaD
Captopril—MMP9—Developmental Biology—CREBBP—urinary bladder cancer	3.78e-05	0.000322	CbGpPWpGaD
Captopril—ALB—Selenium Micronutrient Network—PTGS2—urinary bladder cancer	3.77e-05	0.000321	CbGpPWpGaD
Captopril—F2—Signaling Pathways—HDAC4—urinary bladder cancer	3.77e-05	0.000321	CbGpPWpGaD
Captopril—MMP2—Axon guidance—HRAS—urinary bladder cancer	3.77e-05	0.000321	CbGpPWpGaD
Captopril—F2—Platelet activation, signaling and aggregation—SRC—urinary bladder cancer	3.68e-05	0.000313	CbGpPWpGaD
Captopril—MMP2—Metabolism of proteins—CXCL8—urinary bladder cancer	3.53e-05	0.000301	CbGpPWpGaD
Captopril—CYP2D6—Biological oxidations—GSTP1—urinary bladder cancer	3.52e-05	0.000299	CbGpPWpGaD
Captopril—MMP9—Axon guidance—SRC—urinary bladder cancer	3.51e-05	0.000299	CbGpPWpGaD
Captopril—ABCB1—Allograft Rejection—CXCL8—urinary bladder cancer	3.49e-05	0.000297	CbGpPWpGaD
Captopril—F2—Hemostasis—PLAU—urinary bladder cancer	3.47e-05	0.000296	CbGpPWpGaD
Captopril—CYP2D6—Metapathway biotransformation—GSTP1—urinary bladder cancer	3.47e-05	0.000295	CbGpPWpGaD
Captopril—ABCB1—HIF-1-alpha transcription factor network—EP300—urinary bladder cancer	3.46e-05	0.000295	CbGpPWpGaD
Captopril—MMP9—Developmental Biology—RHOA—urinary bladder cancer	3.42e-05	0.000291	CbGpPWpGaD
Captopril—MMP2—Developmental Biology—EGFR—urinary bladder cancer	3.35e-05	0.000285	CbGpPWpGaD
Captopril—ABCB1—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	3.35e-05	0.000285	CbGpPWpGaD
Captopril—F2—Class A/1 (Rhodopsin-like receptors)—CXCL8—urinary bladder cancer	3.34e-05	0.000284	CbGpPWpGaD
Captopril—ABCB1—Allograft Rejection—IL2—urinary bladder cancer	3.34e-05	0.000284	CbGpPWpGaD
Captopril—F2—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—urinary bladder cancer	3.3e-05	0.000281	CbGpPWpGaD
Captopril—ABCB1—Integrated Pancreatic Cancer Pathway—CCNE1—urinary bladder cancer	3.25e-05	0.000277	CbGpPWpGaD
Captopril—CYP2D6—Biological oxidations—GSTM1—urinary bladder cancer	3.23e-05	0.000275	CbGpPWpGaD
Captopril—ALB—Folate Metabolism—TNF—urinary bladder cancer	3.21e-05	0.000273	CbGpPWpGaD
Captopril—ABCB1—Integrated Pancreatic Cancer Pathway—TYMS—urinary bladder cancer	3.19e-05	0.000272	CbGpPWpGaD
Captopril—MMP2—Developmental Biology—TNF—urinary bladder cancer	3.19e-05	0.000271	CbGpPWpGaD
Captopril—CYP2D6—Metapathway biotransformation—GSTM1—urinary bladder cancer	3.19e-05	0.000271	CbGpPWpGaD
Captopril—ACE—Metabolism of proteins—CXCL8—urinary bladder cancer	3.18e-05	0.00027	CbGpPWpGaD
Captopril—MMP9—Developmental Biology—ERBB2—urinary bladder cancer	3.17e-05	0.00027	CbGpPWpGaD
Captopril—MMP2—Developmental Biology—KRAS—urinary bladder cancer	3.16e-05	0.000269	CbGpPWpGaD
Captopril—F2—Signaling Pathways—GLI1—urinary bladder cancer	3.16e-05	0.000269	CbGpPWpGaD
Captopril—F2—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—urinary bladder cancer	3.12e-05	0.000265	CbGpPWpGaD
Captopril—ALB—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	3.11e-05	0.000265	CbGpPWpGaD
Captopril—MMP9—Axon guidance—EGFR—urinary bladder cancer	3.08e-05	0.000262	CbGpPWpGaD
Captopril—MMP9—Axon guidance—KRAS—urinary bladder cancer	2.91e-05	0.000247	CbGpPWpGaD
Captopril—F2—Hemostasis—CREBBP—urinary bladder cancer	2.86e-05	0.000244	CbGpPWpGaD
Captopril—F2—Hemostasis—IGF1—urinary bladder cancer	2.83e-05	0.000241	CbGpPWpGaD
Captopril—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—urinary bladder cancer	2.83e-05	0.000241	CbGpPWpGaD
Captopril—ALB—Folate Metabolism—TP53—urinary bladder cancer	2.83e-05	0.000241	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—RBX1—urinary bladder cancer	2.8e-05	0.000239	CbGpPWpGaD
Captopril—ABCB1—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	2.73e-05	0.000232	CbGpPWpGaD
Captopril—MMP2—Developmental Biology—HRAS—urinary bladder cancer	2.69e-05	0.000229	CbGpPWpGaD
Captopril—F2—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—urinary bladder cancer	2.65e-05	0.000225	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—TSC1—urinary bladder cancer	2.64e-05	0.000224	CbGpPWpGaD
Captopril—ALB—Metabolism—GSTZ1—urinary bladder cancer	2.61e-05	0.000222	CbGpPWpGaD
Captopril—F2—Hemostasis—RHOA—urinary bladder cancer	2.59e-05	0.000221	CbGpPWpGaD
Captopril—MMP9—Developmental Biology—EP300—urinary bladder cancer	2.58e-05	0.000219	CbGpPWpGaD
Captopril—SLC15A1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	2.55e-05	0.000217	CbGpPWpGaD
Captopril—ALB—Selenium Micronutrient Network—TNF—urinary bladder cancer	2.55e-05	0.000217	CbGpPWpGaD
Captopril—F2—GPCR ligand binding—CXCL8—urinary bladder cancer	2.54e-05	0.000217	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—JAG1—urinary bladder cancer	2.51e-05	0.000214	CbGpPWpGaD
Captopril—MMP9—Developmental Biology—SRC—urinary bladder cancer	2.51e-05	0.000213	CbGpPWpGaD
Captopril—ABCB1—Integrated Pancreatic Cancer Pathway—ATM—urinary bladder cancer	2.5e-05	0.000213	CbGpPWpGaD
Captopril—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—urinary bladder cancer	2.49e-05	0.000212	CbGpPWpGaD
Captopril—ABCB1—Integrated Pancreatic Cancer Pathway—ESR1—urinary bladder cancer	2.48e-05	0.000211	CbGpPWpGaD
Captopril—ALB—Metabolism—GSTO2—urinary bladder cancer	2.47e-05	0.000211	CbGpPWpGaD
Captopril—ALB—Metabolism—NAT1—urinary bladder cancer	2.47e-05	0.000211	CbGpPWpGaD
Captopril—MMP9—Axon guidance—HRAS—urinary bladder cancer	2.47e-05	0.00021	CbGpPWpGaD
Captopril—ALB—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	2.43e-05	0.000207	CbGpPWpGaD
Captopril—ABCB1—Allograft Rejection—TNF—urinary bladder cancer	2.43e-05	0.000207	CbGpPWpGaD
Captopril—ABCB1—Metabolism—GSTZ1—urinary bladder cancer	2.29e-05	0.000195	CbGpPWpGaD
Captopril—ALB—Metabolism—UGT2B7—urinary bladder cancer	2.26e-05	0.000193	CbGpPWpGaD
Captopril—F2—Metabolism of proteins—IGF1—urinary bladder cancer	2.23e-05	0.000189	CbGpPWpGaD
Captopril—MMP9—Developmental Biology—EGFR—urinary bladder cancer	2.2e-05	0.000187	CbGpPWpGaD
Captopril—ALB—Platelet activation, signaling and aggregation—IGF1—urinary bladder cancer	2.18e-05	0.000185	CbGpPWpGaD
Captopril—F2—Hemostasis—IL2—urinary bladder cancer	2.17e-05	0.000185	CbGpPWpGaD
Captopril—ABCB1—Integrated Pancreatic Cancer Pathway—CREBBP—urinary bladder cancer	2.17e-05	0.000185	CbGpPWpGaD
Captopril—ABCB1—Metabolism—GSTO2—urinary bladder cancer	2.17e-05	0.000185	CbGpPWpGaD
Captopril—ABCB1—Metabolism—NAT1—urinary bladder cancer	2.17e-05	0.000185	CbGpPWpGaD
Captopril—F2—Signaling Pathways—RBX1—urinary bladder cancer	2.16e-05	0.000184	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—GSTZ1—urinary bladder cancer	2.15e-05	0.000183	CbGpPWpGaD
Captopril—ABCB1—Integrated Pancreatic Cancer Pathway—IGF1—urinary bladder cancer	2.14e-05	0.000183	CbGpPWpGaD
Captopril—ALB—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	2.1e-05	0.000179	CbGpPWpGaD
Captopril—MMP9—Developmental Biology—TNF—urinary bladder cancer	2.09e-05	0.000178	CbGpPWpGaD
Captopril—MMP9—Developmental Biology—KRAS—urinary bladder cancer	2.07e-05	0.000177	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—GSTO2—urinary bladder cancer	2.04e-05	0.000174	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—NAT1—urinary bladder cancer	2.04e-05	0.000174	CbGpPWpGaD
Captopril—ALB—Metabolism—CYP4B1—urinary bladder cancer	2.04e-05	0.000173	CbGpPWpGaD
Captopril—F2—Signaling Pathways—TSC1—urinary bladder cancer	2.04e-05	0.000173	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—S100B—urinary bladder cancer	2.03e-05	0.000173	CbGpPWpGaD
Captopril—ALB—Platelet activation, signaling and aggregation—RHOA—urinary bladder cancer	2e-05	0.00017	CbGpPWpGaD
Captopril—ABCB1—Metabolism—UGT2B7—urinary bladder cancer	1.98e-05	0.000169	CbGpPWpGaD
Captopril—F2—Hemostasis—EP300—urinary bladder cancer	1.95e-05	0.000166	CbGpPWpGaD
Captopril—ALB—Hemostasis—IFNA2—urinary bladder cancer	1.94e-05	0.000165	CbGpPWpGaD
Captopril—F2—Signaling Pathways—JAG1—urinary bladder cancer	1.94e-05	0.000165	CbGpPWpGaD
Captopril—ALB—Metabolism—SLC19A1—urinary bladder cancer	1.92e-05	0.000164	CbGpPWpGaD
Captopril—F2—Hemostasis—SRC—urinary bladder cancer	1.9e-05	0.000162	CbGpPWpGaD
Captopril—SLC22A6—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	1.89e-05	0.000161	CbGpPWpGaD
Captopril—ALB—Metabolism—PRSS3—urinary bladder cancer	1.87e-05	0.00016	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—UGT2B7—urinary bladder cancer	1.87e-05	0.000159	CbGpPWpGaD
Captopril—ABCB1—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	1.84e-05	0.000157	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—NCOR1—urinary bladder cancer	1.83e-05	0.000156	CbGpPWpGaD
Captopril—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—urinary bladder cancer	1.82e-05	0.000155	CbGpPWpGaD
Captopril—F2—Metabolism of proteins—CXCL8—urinary bladder cancer	1.79e-05	0.000152	CbGpPWpGaD
Captopril—ABCB1—Metabolism—CYP4B1—urinary bladder cancer	1.79e-05	0.000152	CbGpPWpGaD
Captopril—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—urinary bladder cancer	1.78e-05	0.000151	CbGpPWpGaD
Captopril—MMP9—Developmental Biology—HRAS—urinary bladder cancer	1.76e-05	0.00015	CbGpPWpGaD
Captopril—ABCB1—Metabolism—SLC19A1—urinary bladder cancer	1.69e-05	0.000143	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—CYP4B1—urinary bladder cancer	1.68e-05	0.000143	CbGpPWpGaD
Captopril—ALB—Platelet activation, signaling and aggregation—IL2—urinary bladder cancer	1.67e-05	0.000142	CbGpPWpGaD
Captopril—ABCB1—Metabolism—PRSS3—urinary bladder cancer	1.64e-05	0.00014	CbGpPWpGaD
Captopril—F2—GPCR downstream signaling—RHOA—urinary bladder cancer	1.64e-05	0.000139	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—TERT—urinary bladder cancer	1.61e-05	0.000137	CbGpPWpGaD
Captopril—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—urinary bladder cancer	1.61e-05	0.000137	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—SLC19A1—urinary bladder cancer	1.59e-05	0.000135	CbGpPWpGaD
Captopril—F2—Hemostasis—KRAS—urinary bladder cancer	1.57e-05	0.000134	CbGpPWpGaD
Captopril—F2—Signaling Pathways—S100B—urinary bladder cancer	1.57e-05	0.000134	CbGpPWpGaD
Captopril—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—urinary bladder cancer	1.55e-05	0.000132	CbGpPWpGaD
Captopril—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—urinary bladder cancer	1.55e-05	0.000132	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—PRSS3—urinary bladder cancer	1.55e-05	0.000132	CbGpPWpGaD
Captopril—ALB—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	1.5e-05	0.000128	CbGpPWpGaD
Captopril—ALB—Metabolism—TYMP—urinary bladder cancer	1.5e-05	0.000128	CbGpPWpGaD
Captopril—F2—Signaling by GPCR—RHOA—urinary bladder cancer	1.49e-05	0.000127	CbGpPWpGaD
Captopril—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—urinary bladder cancer	1.48e-05	0.000126	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—FGFR3—urinary bladder cancer	1.48e-05	0.000126	CbGpPWpGaD
Captopril—ALB—Platelet activation, signaling and aggregation—SRC—urinary bladder cancer	1.46e-05	0.000124	CbGpPWpGaD
Captopril—ALB—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	1.44e-05	0.000123	CbGpPWpGaD
Captopril—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—urinary bladder cancer	1.44e-05	0.000122	CbGpPWpGaD
Captopril—F2—GPCR downstream signaling—CXCL8—urinary bladder cancer	1.44e-05	0.000122	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—ESR1—urinary bladder cancer	1.44e-05	0.000122	CbGpPWpGaD
Captopril—F2—Signaling Pathways—NCOR1—urinary bladder cancer	1.41e-05	0.00012	CbGpPWpGaD
Captopril—F2—Hemostasis—TP53—urinary bladder cancer	1.4e-05	0.000119	CbGpPWpGaD
Captopril—ALB—Hemostasis—PLAU—urinary bladder cancer	1.38e-05	0.000117	CbGpPWpGaD
Captopril—F2—GPCR downstream signaling—IL2—urinary bladder cancer	1.37e-05	0.000117	CbGpPWpGaD
Captopril—ALB—Metabolism—NAT2—urinary bladder cancer	1.36e-05	0.000115	CbGpPWpGaD
Captopril—F2—Hemostasis—HRAS—urinary bladder cancer	1.34e-05	0.000114	CbGpPWpGaD
Captopril—ABCB1—Metabolism—TYMP—urinary bladder cancer	1.31e-05	0.000112	CbGpPWpGaD
Captopril—F2—Signaling by GPCR—CXCL8—urinary bladder cancer	1.31e-05	0.000111	CbGpPWpGaD
Captopril—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	1.29e-05	0.00011	CbGpPWpGaD
Captopril—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	1.26e-05	0.000107	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—CREBBP—urinary bladder cancer	1.26e-05	0.000107	CbGpPWpGaD
Captopril—F2—Signaling by GPCR—IL2—urinary bladder cancer	1.25e-05	0.000106	CbGpPWpGaD
Captopril—F2—Signaling Pathways—TERT—urinary bladder cancer	1.24e-05	0.000106	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—IGF1—urinary bladder cancer	1.24e-05	0.000106	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—TYMP—urinary bladder cancer	1.24e-05	0.000105	CbGpPWpGaD
Captopril—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	1.2e-05	0.000102	CbGpPWpGaD
Captopril—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	1.19e-05	0.000101	CbGpPWpGaD
Captopril—ABCB1—Metabolism—NAT2—urinary bladder cancer	1.19e-05	0.000101	CbGpPWpGaD
Captopril—ALB—Metabolism—RRM2—urinary bladder cancer	1.17e-05	9.96e-05	CbGpPWpGaD
Captopril—F2—Signaling Pathways—FGFR3—urinary bladder cancer	1.14e-05	9.71e-05	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—RHOA—urinary bladder cancer	1.14e-05	9.69e-05	CbGpPWpGaD
Captopril—ALB—Hemostasis—CREBBP—urinary bladder cancer	1.14e-05	9.68e-05	CbGpPWpGaD
Captopril—ALB—Hemostasis—IGF1—urinary bladder cancer	1.12e-05	9.56e-05	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—NAT2—urinary bladder cancer	1.12e-05	9.53e-05	CbGpPWpGaD
Captopril—F2—Signaling Pathways—ESR1—urinary bladder cancer	1.11e-05	9.43e-05	CbGpPWpGaD
Captopril—ALB—Metabolism—HPGDS—urinary bladder cancer	1.08e-05	9.22e-05	CbGpPWpGaD
Captopril—ALB—Metabolism—ENO2—urinary bladder cancer	1.08e-05	9.22e-05	CbGpPWpGaD
Captopril—ALB—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	1.08e-05	9.17e-05	CbGpPWpGaD
Captopril—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	1.06e-05	9.01e-05	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—ERBB2—urinary bladder cancer	1.05e-05	8.97e-05	CbGpPWpGaD
Captopril—ALB—Metabolism—GSTT1—urinary bladder cancer	1.05e-05	8.95e-05	CbGpPWpGaD
Captopril—ALB—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.03e-05	8.81e-05	CbGpPWpGaD
Captopril—ALB—Hemostasis—RHOA—urinary bladder cancer	1.03e-05	8.75e-05	CbGpPWpGaD
Captopril—ABCB1—Metabolism—RRM2—urinary bladder cancer	1.03e-05	8.73e-05	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—CXCL8—urinary bladder cancer	9.99e-06	8.5e-05	CbGpPWpGaD
Captopril—ALB—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	9.84e-06	8.38e-05	CbGpPWpGaD
Captopril—F2—Signaling Pathways—CREBBP—urinary bladder cancer	9.71e-06	8.27e-05	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—RRM2—urinary bladder cancer	9.66e-06	8.22e-05	CbGpPWpGaD
Captopril—F2—Signaling Pathways—IGF1—urinary bladder cancer	9.59e-06	8.16e-05	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—IL2—urinary bladder cancer	9.55e-06	8.13e-05	CbGpPWpGaD
Captopril—F2—Signaling by GPCR—EGFR—urinary bladder cancer	9.54e-06	8.12e-05	CbGpPWpGaD
Captopril—ABCB1—Metabolism—HPGDS—urinary bladder cancer	9.49e-06	8.08e-05	CbGpPWpGaD
Captopril—ABCB1—Metabolism—ENO2—urinary bladder cancer	9.49e-06	8.08e-05	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—CCND1—urinary bladder cancer	9.31e-06	7.92e-05	CbGpPWpGaD
Captopril—ABCB1—Metabolism—GSTT1—urinary bladder cancer	9.21e-06	7.84e-05	CbGpPWpGaD
Captopril—F2—Signaling by GPCR—KRAS—urinary bladder cancer	9.02e-06	7.67e-05	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—CDKN1A—urinary bladder cancer	9e-06	7.66e-05	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—PTEN—urinary bladder cancer	8.98e-06	7.65e-05	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—ENO2—urinary bladder cancer	8.95e-06	7.62e-05	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—HPGDS—urinary bladder cancer	8.95e-06	7.62e-05	CbGpPWpGaD
Captopril—F2—Signaling Pathways—RHOA—urinary bladder cancer	8.79e-06	7.48e-05	CbGpPWpGaD
Captopril—ALB—Metabolism—NQO1—urinary bladder cancer	8.73e-06	7.43e-05	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—GSTT1—urinary bladder cancer	8.68e-06	7.39e-05	CbGpPWpGaD
Captopril—ALB—Hemostasis—IL2—urinary bladder cancer	8.63e-06	7.34e-05	CbGpPWpGaD
Captopril—ABCB1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	8.62e-06	7.34e-05	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—EP300—urinary bladder cancer	8.57e-06	7.29e-05	CbGpPWpGaD
Captopril—ALB—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	8.47e-06	7.21e-05	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—SRC—urinary bladder cancer	8.33e-06	7.09e-05	CbGpPWpGaD
Captopril—F2—Signaling Pathways—ERBB2—urinary bladder cancer	8.13e-06	6.92e-05	CbGpPWpGaD
Captopril—ALB—Hemostasis—EP300—urinary bladder cancer	7.74e-06	6.59e-05	CbGpPWpGaD
Captopril—F2—Signaling Pathways—CXCL8—urinary bladder cancer	7.71e-06	6.57e-05	CbGpPWpGaD
Captopril—F2—Signaling by GPCR—HRAS—urinary bladder cancer	7.66e-06	6.52e-05	CbGpPWpGaD
Captopril—ABCB1—Metabolism—NQO1—urinary bladder cancer	7.65e-06	6.51e-05	CbGpPWpGaD
Captopril—ALB—Hemostasis—SRC—urinary bladder cancer	7.53e-06	6.41e-05	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—MYC—urinary bladder cancer	7.47e-06	6.35e-05	CbGpPWpGaD
Captopril—ALB—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	7.39e-06	6.29e-05	CbGpPWpGaD
Captopril—F2—Signaling Pathways—IL2—urinary bladder cancer	7.37e-06	6.27e-05	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—EGFR—urinary bladder cancer	7.3e-06	6.22e-05	CbGpPWpGaD
Captopril—ALB—Metabolism—GSTP1—urinary bladder cancer	7.29e-06	6.2e-05	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—NQO1—urinary bladder cancer	7.21e-06	6.14e-05	CbGpPWpGaD
Captopril—F2—Signaling Pathways—CCND1—urinary bladder cancer	7.19e-06	6.12e-05	CbGpPWpGaD
Captopril—ALB—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	7.05e-06	6e-05	CbGpPWpGaD
Captopril—F2—Signaling Pathways—MMP9—urinary bladder cancer	6.98e-06	5.94e-05	CbGpPWpGaD
Captopril—F2—Signaling Pathways—CDKN1A—urinary bladder cancer	6.95e-06	5.92e-05	CbGpPWpGaD
Captopril—F2—Signaling Pathways—PTEN—urinary bladder cancer	6.94e-06	5.9e-05	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—KRAS—urinary bladder cancer	6.9e-06	5.87e-05	CbGpPWpGaD
Captopril—ALB—Metabolism—TYMS—urinary bladder cancer	6.77e-06	5.76e-05	CbGpPWpGaD
Captopril—ALB—Metabolism—GSTM1—urinary bladder cancer	6.69e-06	5.7e-05	CbGpPWpGaD
Captopril—ALB—Metabolism—NCOR1—urinary bladder cancer	6.69e-06	5.7e-05	CbGpPWpGaD
Captopril—F2—Signaling Pathways—EP300—urinary bladder cancer	6.62e-06	5.63e-05	CbGpPWpGaD
Captopril—F2—Signaling Pathways—SRC—urinary bladder cancer	6.43e-06	5.48e-05	CbGpPWpGaD
Captopril—ALB—Metabolism—GPX1—urinary bladder cancer	6.41e-06	5.46e-05	CbGpPWpGaD
Captopril—ABCB1—Metabolism—GSTP1—urinary bladder cancer	6.38e-06	5.43e-05	CbGpPWpGaD
Captopril—ALB—Metabolism—ERCC2—urinary bladder cancer	6.29e-06	5.36e-05	CbGpPWpGaD
Captopril—ALB—Hemostasis—KRAS—urinary bladder cancer	6.23e-06	5.31e-05	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—TP53—urinary bladder cancer	6.13e-06	5.22e-05	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—GSTP1—urinary bladder cancer	6.02e-06	5.12e-05	CbGpPWpGaD
Captopril—ABCB1—Metabolism—TYMS—urinary bladder cancer	5.93e-06	5.05e-05	CbGpPWpGaD
Captopril—ALB—Metabolism—MTHFR—urinary bladder cancer	5.92e-06	5.04e-05	CbGpPWpGaD
Captopril—ABCB1—Metabolism—GSTM1—urinary bladder cancer	5.87e-06	4.99e-05	CbGpPWpGaD
Captopril—ABCB1—Metabolism—NCOR1—urinary bladder cancer	5.87e-06	4.99e-05	CbGpPWpGaD
Captopril—MMP9—Signaling Pathways—HRAS—urinary bladder cancer	5.86e-06	4.99e-05	CbGpPWpGaD
Captopril—F2—Signaling Pathways—MYC—urinary bladder cancer	5.76e-06	4.91e-05	CbGpPWpGaD
Captopril—F2—Signaling Pathways—EGFR—urinary bladder cancer	5.64e-06	4.8e-05	CbGpPWpGaD
Captopril—ABCB1—Metabolism—GPX1—urinary bladder cancer	5.62e-06	4.78e-05	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—TYMS—urinary bladder cancer	5.59e-06	4.76e-05	CbGpPWpGaD
Captopril—ALB—Hemostasis—TP53—urinary bladder cancer	5.54e-06	4.72e-05	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—GSTM1—urinary bladder cancer	5.53e-06	4.7e-05	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—NCOR1—urinary bladder cancer	5.53e-06	4.7e-05	CbGpPWpGaD
Captopril—ABCB1—Metabolism—ERCC2—urinary bladder cancer	5.52e-06	4.69e-05	CbGpPWpGaD
Captopril—F2—Signaling Pathways—KRAS—urinary bladder cancer	5.33e-06	4.53e-05	CbGpPWpGaD
Captopril—ALB—Hemostasis—HRAS—urinary bladder cancer	5.3e-06	4.51e-05	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—GPX1—urinary bladder cancer	5.29e-06	4.51e-05	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—ERCC2—urinary bladder cancer	5.2e-06	4.42e-05	CbGpPWpGaD
Captopril—ABCB1—Metabolism—MTHFR—urinary bladder cancer	5.18e-06	4.41e-05	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—MTHFR—urinary bladder cancer	4.89e-06	4.16e-05	CbGpPWpGaD
Captopril—ALB—Metabolism—PPARG—urinary bladder cancer	4.8e-06	4.08e-05	CbGpPWpGaD
Captopril—F2—Signaling Pathways—TP53—urinary bladder cancer	4.73e-06	4.03e-05	CbGpPWpGaD
Captopril—ALB—Metabolism—CREBBP—urinary bladder cancer	4.61e-06	3.92e-05	CbGpPWpGaD
Captopril—F2—Signaling Pathways—HRAS—urinary bladder cancer	4.53e-06	3.85e-05	CbGpPWpGaD
Captopril—ABCB1—Metabolism—PPARG—urinary bladder cancer	4.2e-06	3.58e-05	CbGpPWpGaD
Captopril—ABCB1—Metabolism—CREBBP—urinary bladder cancer	4.04e-06	3.44e-05	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—PPARG—urinary bladder cancer	3.96e-06	3.37e-05	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—CREBBP—urinary bladder cancer	3.81e-06	3.24e-05	CbGpPWpGaD
Captopril—ALB—Metabolism—PTGS2—urinary bladder cancer	3.77e-06	3.21e-05	CbGpPWpGaD
Captopril—ABCB1—Metabolism—PTGS2—urinary bladder cancer	3.31e-06	2.81e-05	CbGpPWpGaD
Captopril—ALB—Metabolism—PTEN—urinary bladder cancer	3.29e-06	2.8e-05	CbGpPWpGaD
Captopril—ALB—Metabolism—EP300—urinary bladder cancer	3.14e-06	2.67e-05	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—PTGS2—urinary bladder cancer	3.12e-06	2.65e-05	CbGpPWpGaD
Captopril—ABCB1—Metabolism—PTEN—urinary bladder cancer	2.88e-06	2.45e-05	CbGpPWpGaD
Captopril—ABCB1—Metabolism—EP300—urinary bladder cancer	2.75e-06	2.34e-05	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—PTEN—urinary bladder cancer	2.72e-06	2.31e-05	CbGpPWpGaD
Captopril—CYP2D6—Metabolism—EP300—urinary bladder cancer	2.59e-06	2.21e-05	CbGpPWpGaD
